Skip to content

LBRX LBRX Other operating expenses

Other operating expenses at other companies

MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$64.5M+174%
Alto Neuroscience logo
Alto NeuroscienceANRO
$27.14M+73.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
$39.82M+52.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$44.22M+63.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$112.33M+40.0%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's other operating expenses?
LBRX (LBRX) reported other operating expenses of $22.1M in Q1 2026.
How has LBRX's other operating expenses changed year-over-year?
LBRX's other operating expenses increased by 243.8% year-over-year, from $6.43M to $22.1M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.